In short
CLN-081, also known as TAS6417 or zipalertinib, is an investigational drug currently being studied in clinical trials for patients with non-small cell lung cancer (NSCLC) who have a specific genetic mutation called EGFR exon 20 insertion. This article will explore the ongoing research, potential benefits, and important information about CLN-081 in its clinical trial journey.
At a glance
- Drug Name
- CLN-081 (also known as TAS6417 or zipalertinib)
- Target Condition
- Non-Small Cell Lung Cancer (NSCLC) with EGFR Exon 20 Insertion Mutations
- Trial Phase
- Phase 1/2
- Administration
- Oral tablets, twice daily (BID)
- Primary Objectives
- Safety, tolerability, pharmacokinetics, pharmacodynamics, efficacy
- Key Outcomes Measured
- Adverse events, dose-limiting toxicities, overall response rate, duration of response
- Trial Structure
- Multiple parts including dose escalation, dose expansion, and food effect study
- Patient Population
- NSCLC patients with EGFR exon 20 insertion mutations, including those who have received prior treatments
What is CLN-081?
CLN-081, also known as TAS6417 or zipalertinib, is a new drug being studied for the treatment of a specific type of lung cancer. It is designed to target a particular genetic mutation found in some lung cancer patients, offering hope for more effective and targeted treatment options.
Target Condition: NSCLC with EGFR Exon 20 Insertion Mutations
CLN-081 is being developed to treat non-small cell lung cancer (NSCLC) with a specific genetic change called EGFR exon 20 insertion mutations. To understand this better:
- Non-small cell lung cancer (NSCLC): This is the most common type of lung cancer, accounting for about 80-85% of all lung cancers.
- EGFR (Epidermal Growth Factor Receptor): This is a protein on cells that helps them grow and divide. Some NSCLC cells have too much EGFR, which makes them grow faster.
- Exon 20 insertion mutations: These are specific changes in the EGFR gene that can make lung cancer cells grow and spread more aggressively.
Clinical Trial Overview
The clinical trial for CLN-081 is a Phase 1/2 study, which means it's in the early stages of testing in humans. The trial is designed to:
- Determine if CLN-081 is safe for patients
- Find the right dose of the drug
- See how well it works against NSCLC with EGFR exon 20 insertion mutations
This trial is particularly important for patients who have already received platinum-based chemotherapy, as it may offer a new treatment option for those who have not responded well to standard treatments.
Trial Objectives
The clinical trial is divided into several parts, each with specific goals:
- Phase 1 Dose Escalation: To find the safest and most effective dose of CLN-081
- Phase 2a Dose Expansion: To further test the chosen dose in more patients
- Module A: To see how food affects how the body processes CLN-081
- Module B: To study CLN-081 in patients who have received other cancer treatments before
- Module C: To explore how CLN-081 works in patients who have already tried other drugs specifically approved for EGFR exon 20 insertion mutant NSCLC
Dosing and Administration
CLN-081 is given as a tablet that patients take by mouth twice daily (BID). The exact dose may vary depending on which part of the trial a patient is in. Some parts of the study are also looking at how taking the drug with or without food might affect its effectiveness.
Safety and Efficacy Measures
The researchers are carefully monitoring several aspects of CLN-081's performance:
- Safety: They're tracking any side effects (called adverse events or AEs) that patients experience.
- Efficacy: They're measuring how well the drug works by looking at:
- Overall response rate (ORR): The percentage of patients whose cancer shrinks or disappears after treatment.
- Duration of response (DOR): How long the cancer stays smaller or gone after treatment.
- Disease control rate (DCR): The percentage of patients whose cancer shrinks or stays the same size.
- Progression-free survival (PFS): How long patients live without their cancer getting worse.
- Overall survival (OS): How long patients live overall.
- Pharmacokinetics: They're studying how the body processes the drug by measuring things like how much of the drug gets into the bloodstream and how long it stays there.
Potential Benefits for Patients
While it's important to remember that CLN-081 is still in the testing phase, it offers several potential benefits for patients with NSCLC and EGFR exon 20 insertion mutations:
- It may provide a new treatment option for patients who have not responded well to other therapies.
- As a targeted therapy, it may have fewer side effects than traditional chemotherapy.
- It's taken orally, which can be more convenient for patients than treatments given by injection or infusion.
- If successful, it could improve survival and quality of life for patients with this specific type of lung cancer.
As research continues, more information about CLN-081's effectiveness and safety will become available, potentially offering new hope for lung cancer patients with this specific genetic mutation.